期刊文献+

沙格列汀或格列美脲联合甘精胰岛素对2型糖尿病患者血糖波动影响的观察 被引量:61

Effects of saxagliptin or glimepiride combined with glargine on blood glucose fluctuations in type 2 diabetic patients
原文传递
导出
摘要 目的观察沙格列汀联合甘精胰岛素及格列美脲联合甘精胰岛素对T2DM患者血糖波动的影响。方法 60例未接受胰岛素治疗且血糖控制不佳的T2DM患者被随机分为沙格列汀联合甘精胰岛素组和格列美脲联合甘精胰岛素组,共治疗12周。采用动态血糖监测系统(CGMS)监测血糖波动情况,观察BMI、FPG、HbA1c及胰岛素用量等指标。结果两组血糖控制均改善,沙格列汀联合甘精胰岛素组日内血糖平均波动幅度(MAGE)、日内血糖波动次数(NGE)、日间血糖平均绝对差(MODD)低于格列美脲联合甘精胰岛素组[(2.2±1.0)vs(4.1±1.9)mmol/L;(1.4±1.4)vs(2.6±1.5)次/d;(1.30±0.65)vs(2.60±0.90)mmol/L,P<0.05]。两组治疗后FPG及HbA1c均降低[沙格列汀联合甘精胰岛素组(10.5±2.1)vs(6.2±1.3)mmol/L,(8.7±1.2)%vs(6.3±1.1)%;格列美脲联合甘精胰岛素组(10.4±1.8)vs(6.1±1.4)mmol/L,(8.9±1.4)%vs(6.5±1.2)%](P均<0.01);沙格列汀联合甘精胰岛素组BMI低于格列美脲联合甘精胰岛素组[(22.2±2.4)vs(25.5±2.7)kg/m2](P<0.05)。结论沙格列汀联合甘精胰岛素可有效控制血糖,改善血糖波动,在血糖控制稳定性方面优于格列美脲联合甘精胰岛素。 Objective To investigate the effect of saxagliptin plus glargine or glimepiride plus glargine on blood glucose fluctuations in T2DM patients. Methods A total of 60 T2DM patients with unsatisfactory glycemic control who did not receive insulin therapy were randomly assigned to saxagliptin plus glargine group and glimepiride plus glargine group. They were followed up for 12 weeks. During the treatment, continuous glucose monitoring system (CGMS) was used to evaluate the blood glucose fluctuations. BMI, FPG, HbA1 c, insulin dosage and other clinical characteristics were recorded. Results Glycemic control was improved in both groups. Mean amplitude of glycemic excursions (MAGE), number of glycemic excursion (NGE), mean of daily differences (MODD) were lower in saxagliptin group than in glimepiride group [(2.24±1.0)vs(4.14±1.9)mmol/L; (1.4±1.4)vs(2.6±1.5) times/d; (1.30±0.65)vs (2.60±0.90) retool/L, P〈0.05]. FPG and HbAlc were decreased after treatment in both groups [-saxagliptin group ; ( 10. 5 ± 2.1 ) vs ( 6.2 ±1.3 ) mmol/L, ( 8.7 4± 1.2 ) % vs ( 6.3± 1.1 ) %glimepiride group: (10.4±1.8)vs(6.1±1.4)retool/L, (8. 9±1.4)~ vs(6.5±1.2)%]. BMI was significantly lower in saxagliptin group than in glimepiride group [ ( 22.2 ± 2.4) vs ( 25.5 ± 2.7 ) kg/m2, P 〈0. 05 ]. Conclusion Saxagliptin plus glargine can effectively control blood glucose level and improve blood glucose fluctuations. Compared with glimepiride plus glargine, blood glucose control is much stable in saxagliptin plus glargine treatment.
出处 《中国糖尿病杂志》 CAS CSCD 北大核心 2015年第3期237-240,共4页 Chinese Journal of Diabetes
关键词 沙格列汀 格列美脲 甘精胰岛素 血糖波动 动态血糖监测 糖尿病 2型 Saxagliptin Glimepiride Glargine Blood glucose fluctuation Continuous glucosemonitoring Diabetes mellitus, type 2
  • 相关文献

参考文献6

  • 1Ceriello A, Ihnat MA. Glycaemic variability: a new therapeutic challenge in diabetes and the critical care setting. Diabet Med, 2010,27 : 862-867.
  • 2Hsu CW. Glycemic control in critically ill patients. World J Crit Care Med,2012,1:31 39.
  • 3Egi M,Bellomo R,Stachowski E,et al. Variability of blood glu- cose concentration and short-term mortality in critically ill pa- tients. Anesthesiology, 2006,105 : 244 252.
  • 4Hirsch IB, Brownlee M. Should minimal blood glucose variabili ty become the gold standard control? J Diabetes Complica tions, 2005,19 : 178 181.
  • 5Vilsboll T, Rosenstock J, Yki-Jfirvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab,2010,12:167-177.
  • 6He YL, Foteinos G, Neelakantham S, et al. Differential effects of vildagliptin and glimepiride onglucose fluctuations in patients with type 2 diabetesmellitus assessed using continuous glucose monitoring. Diabetes Obes Metab, 2013,15 : 1111-1119.

同被引文献494

引证文献61

二级引证文献329

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部